Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil.
Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs. This review will examine a novel AAD, tedisamil--a multichannel potassium channel blocker--and its antiarrhythmic properties, focusing on AF. Review of the literature and studies assessing the effect of tedisamil in humans and animal models with atrial arrhythmia(s). Tedisamil appears to be effective for rhythm restoration in acute-onset AF patients. The proven anti-ischemic effect with tedisamil may be an added benefit. Further studies with tedisamil are needed to confirm its safety and long-term efficacy.